Table 2 SIRs for type 2 diabetes mellitus after a specified autoimmune disease by gender.

From: Subsequent Type 2 Diabetes in Patients with Autoimmune Disease

Autoimmune disease

All

Male

Female

O

SIR

95% CI

O

SIR

95% CI

O

SIR

95% CI

Addison disease

108

2.63

2.16–3.18

38

2.04

1.44–2.80

70

3.14

2.44–3.96

Amyotrophic lateral sclerosis

43

0.84

0.61–1.14

29

0.83

0.56–1.20

14

0.87

0.47–1.46

Ankylosing spondylitis

314

1.32

1.17–1.47

223

1.23

1.08–1.40

91

1.58

1.27–1.94

Autoimmune hemolytic anemia

21

1.77

1.09–2.71

12

2.04

1.05–3.58

9

1.51

0.68–2.87

Behcet disease

81

1.24

0.98–1.54

58

1.18

0.89–1.52

23

1.41

0.90–2.13

Celiac disease

251

1.10

0.96–1.24

134

1.22

1.02–1.44

117

0.98

0.81–1.18

Chorea minor

10

8.00

3.81–14.77

4

8.34

2.17–21.56

6

7.79

2.80–17.07

Chronic rheumatic heart disease

476

1.66

1.51–1.82

229

1.44

1.26–1.64

247

1.94

1.70–2.20

Crohn disease

713

1.54

1.43–1.66

407

1.51

1.37–1.67

306

1.58

1.41–1.77

Discoid lupus erythematosus

60

1.09

0.83–1.41

22

1.15

0.72–1.74

38

1.06

0.75–1.46

Graves/hyperthyroidism

1772

1.47

1.41–1.54

410

1.49

1.35–1.64

1362

1.47

1.39–1.55

Hashimoto/hypothyroidism

2013

2.01

1.92–2.10

430

2.09

1.89–2.29

1583

1.99

1.89–2.09

Immune thrombocytopenic purpura

182

2.46

2.12–2.85

97

2.42

1.96–2.96

85

2.51

2.00–3.10

Localized scleroderma

75

1.72

1.35–2.15

22

1.90

1.19–2.88

53

1.65

1.24–2.16

Lupoid hepatitis

68

5.75

4.46–7.29

23

5.41

3.42–8.13

45

5.94

4.33–7.95

Multiple sclerosis

303

1.22

1.09–1.37

120

1.12

0.92–1.33

183

1.30

1.12–1.51

Myasthenia gravis

92

1.68

1.36–2.06

53

1.79

1.34–2.34

39

1.56

1.11–2.13

Pernicious anemia

140

1.21

1.01–1.42

86

1.39

1.11–1.72

54

0.99

0.75–1.30

Polyarteritis nodosa

52

2.01

1.50–2.64

30

2.21

1.49–3.16

22

1.79

1.12–2.71

Polymyalgia rheumatica

1900

1.82

1.74–1.91

724

1.68

1.56–1.81

1176

1.92

1.81–2.03

Polymyositis/dermatomyositis

94

2.10

1.70–2.58

51

2.32

1.73–3.05

43

1.90

1.37–2.56

Primary biliary cirrhosis

96

2.18

1.77–2.66

26

2.63

1.72–3.86

70

2.05

1.60–2.59

Psoriasis

3028

2.03

1.96–2.10

1579

1.88

1.78–1.97

1449

2.22

2.11–2.34

Reiter disease

14

1.20

0.65–2.02

12

1.17

0.60–2.06

2

1.40

0.13–5.14

Rheumatic fever

118

1.32

1.09–1.58

84

1.20

0.96–1.49

34

1.77

1.22–2.47

Rheumatoid arthritis

2070

1.50

1.44–1.57

788

1.52

1.42–1.63

1282

1.49

1.41–1.57

Sarcoidosis

646

2.11

1.95–2.28

346

2.02

1.81–2.24

300

2.24

1.99–2.51

Sjögren syndrome

353

1.52

1.37–1.69

65

1.67

1.29–2.12

288

1.50

1.33–1.68

Systemic lupus erythematosus

201

1.83

1.59–2.10

44

1.50

1.09–2.02

157

1.95

1.66–2.28

Systemic sclerosis

129

1.34

1.12–1.60

71

1.44

1.13–1.82

58

1.24

0.94–1.61

Ulcerative colitis

1359

1.73

1.64–1.82

875

1.77

1.66–1.89

484

1.65

1.51–1.81

Wegener granulomatosis

215

1.45

1.26–1.66

80

1.44

1.14–1.79

135

1.46

1.22–1.73

All

15103

1.66

1.63–1.68

6519

1.62

1.58–1.66

8584

1.68

1.65–1.72

  1. Bold type indicates that the 95% CI does not include 1.00.
  2. Abbreviations: O, observed; SIR, standardized incidence ratio; CI, confidence interval.
Back to article page